Journal of Cutaneous and Aesthetic Surgery

CORRESPONDENCE
Year
: 2015  |  Volume : 8  |  Issue : 4  |  Page : 245--247

Successful treatment of recalcitrant Bowen's disease of the lower back using a bimodal approach


Aditya Kumar Bubna 
 Department of Dermatology, Sri Ramachandra University, Chennai, Tamil Nadu, India

Correspondence Address:
Aditya Kumar Bubna
Department of Dermatology, Sri Ramachandra University, Chennai, Tamil Nadu
India




How to cite this article:
Bubna AK. Successful treatment of recalcitrant Bowen's disease of the lower back using a bimodal approach.J Cutan Aesthet Surg 2015;8:245-247


How to cite this URL:
Bubna AK. Successful treatment of recalcitrant Bowen's disease of the lower back using a bimodal approach. J Cutan Aesthet Surg [serial online] 2015 [cited 2021 Sep 27 ];8:245-247
Available from: https://www.jcasonline.com/text.asp?2015/8/4/245/172208


Full Text

Dear Editor,

Bowen's disease (BD) is basically squamous cell carcinoma in situ, which if not adequately managed may develop into invasive carcinoma. Multiple therapeutic options are available for managing BD. The treatment option chosen depends on the availability, patient preference, clinical circumstance, and the expertise of the clinician with respect to that particular modality of treatment instituted. It has also been seen that a patient not responding to a particular form of treatment may respond fairly well to another form of treatment, and a combination of two or more treatment modalities in such cases may complement one other, thus facilitating a quicker resolution and allowing better patient compliance.

My patient was a 61-year-old gentleman who presented with a discolored, firm, nontender plaque of size 8 × 7 cm over the lower back [Figure 1] since the past 8 months. It was a tiny lesion to begin with, that had gradually progressed to attain the current status. Associated symptoms of tingling and burning were present over the lesion. Previous treatment included topical usage of 5% imiquimod cream for a period of 16 weeks with no significant improvement. An incisional biopsy from the lesion revealed complete epidermal dysplasia, with keratinocytes demonstrating nuclear atypia and the classic wind-blown appearance [Figure 2] and [Figure 3], which confirmed the diagnosis of BD. After counseling the patient with regard to the available treatment modalities and obtaining an informed consent, the lesional site was ablated utilizing carbon dioxide (CO 2) laser at 10-Hz frequency in the super-pulsed mode, including 5-mm margins of the surrounding normal skin till pinpoint bleeding spots were obtained [Figure 4]. A review after 6 weeks demonstrated good reepithelialization of the lesion [Figure 5]. However, a smoldering pain still persisted at the lesional site. A rebiopsy from the lased site demonstrated the presence of a few atypical cells in and around the adnexa. Taking this into consideration, 5-fluorouracil (5-FU) was instilled into the lesion, after dividing it into four quadrants with 2 mL of 5-FU being injected into each quadrant. The patient was regularly followed up at monthly intervals. Surprisingly, after intralesional instillation of 5-FU, there was complete disappearance of pain, which the patient had earlier complained about. With each review, the lesion demonstrated improvement in color and texture, gradually blending with the surrounding skin [Figure 6], [Figure 7] and [Figure 8]. A biopsy performed after 12 months showed no evidence of BD. The patient was reassured.{Figure 1}{Figure 2}{Figure 3}{Figure 4}{Figure 5}{Figure 6}{Figure 7}{Figure 8}

CO 2 laser has been a very effective treatment modality for treating cutaneous premalignant conditions. However, its beneficial effects are limited to the epidermis and superficial dermis. [1] With laser injury penetrating deeper, unacceptable cosmesis is unavoidable. [2] Therefore, to counteract this, intralesional instillation of cytotoxic agents could prove beneficial. 5-FU has been employed as an intralesional agent in managing cutaneous neoplasms. 5-FU is a pyrimidine antagonist specifically targeting thymidylate synthetase, and disrupting DNA synthesis in mitotically active cells. [3] In these patients 5-FU is injected every week for a period of 6-8 weeks. The major disadvantage of this schedule is the unpractical nature of the procedure in lesions >5 × 5 cm in size and the painful quality of the procedure. [4],[5] In such cases, it would be prudent to combine two treatment modalities, thus facilitating a good therapeutic outcome. In this case, the superficial pathology was dealt with CO 2 laser and the deeper remnant with 5-FU, one session of each, thus avoiding multiple painful sessions of intralesional 5-FU. The author feels that in dealing with larger lesions of Bowen's disease, this combination approach would be useful as immediately post CO 2 laser ablation, the patient is able to decipher visible changes in his/her lesion thereby heralding a better adherence to therapy, avoidance of multiple painful sessions of 5-FU injections, and above all a better therapeutic outcome.

Acknowledgement

I would like to thank Dr. Poornima ARC and Dr. Sindhu, residents of the Department of Dermatology, Sri Ramachandra University, Chennai, Tamil Nadu, India for helping me in clinical photography.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1Fader DJ, Lowe L. Concomitant use of a high-energy pulsed CO2 laser and a long-pulsed (810 nm) diode laser for squamous cell carcinoma in situ. Dermatol Surg 2002;28:97-100.
2Olbricht SM, Stern RS, Tang SV, Noe JM, Arndt KA. Complications of cutaneous laser surgery. A survey. Arch Dermatol 1987;123:345-9.
3Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: Mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:330-8.
4Morse LG, Kendrick C, Hooper D, Ward H, Parry E. Treatment of squamous cell carcinoma with intralesional 5-fluorouracil. Dermatol Surg 2003;29:1150-3.
5Miller BH, Shavin JS, Cognetta A, Taylor JR, Salasche S, Korey A, et al. Nonsurgical treatment of basal cell carcinomas with intralesional 5-Fluorouracil/epinephrine injectable gel. J Am Acad Dermatol 1997;36:72-7.